- Previous Close
14.36 - Open
13.68 - Bid 13.53 x 100
- Ask 13.67 x 100
- Day's Range
13.32 - 13.93 - 52 Week Range
11.70 - 19.16 - Volume
291,900 - Avg. Volume
383,549 - Market Cap (intraday)
577.362M - Beta (5Y Monthly) 1.02
- PE Ratio (TTM)
-- - EPS (TTM)
-0.75 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
24.67
SI-BONE, Inc., a medical device company, focuses on solving musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. The company offers proprietary minimally invasive surgical implant systems to address sacroiliac joint dysfunction and degeneration, adult deformity and degeneration, and pelvic trauma, as well as implantable bone products. It also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with a proprietary 3D-printed porous surface and fenestrated design; iFuse TORQ, a line of 3D-printed threaded implants designed for applications in pelvic trauma and sacroliliac fusion; and iFuse Bedrock Granite Implant System that provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion; and iFuse TORQ TNT to treat pelvic trauma and sacroiliac joint dysfunction, as well as iFuse INTRA implants that are marketed as human cells, tissues, and cellular or tissue-based products. The company markets its products primarily with a direct sales force, as well as through third-party sales agent and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
si-bone.comRecent News: SIBN
View MorePerformance Overview: SIBN
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SIBN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SIBN
View MoreValuation Measures
Market Cap
577.79M
Enterprise Value
465.23M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.38
Price/Book (mrq)
3.46
Enterprise Value/Revenue
2.78
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-18.49%
Return on Assets (ttm)
-9.56%
Return on Equity (ttm)
-18.38%
Revenue (ttm)
167.18M
Net Income Avi to Common (ttm)
-30.91M
Diluted EPS (ttm)
-0.75
Balance Sheet and Cash Flow
Total Cash (mrq)
150.04M
Total Debt/Equity (mrq)
22.45%
Levered Free Cash Flow (ttm)
-12.7M